What is Resonea?
Established in 2016, Resonea is dedicated to enhancing the science of sleep health to boost performance, safety, and overall quality of life. The company's flagship product, DROWZLE® PRO, is the first FDA-cleared, smartphone-based home sleep test. This groundbreaking technology revolutionizes the detection of obstructive sleep apnea by leveraging mobile phone capabilities, thereby expanding access to crucial sleep health services while ensuring patient comfort and safety within their homes. Resonea's focus on accessible sleep diagnostics positions it as a key player in the digital health sector.
How much funding has Resonea raised?
Resonea has raised a total of $348K across 2 funding rounds:
Debt
$150K
Debt
$198K
Debt (2020): $150K with participation from PPP
Debt (2021): $198K led by PPP
What's next for Resonea?
With its recent substantial investment and a clear late-stage funding context, Resonea is poised for significant scaling and market penetration. The strategic capital infusion is expected to accelerate product development, enhance its DROWZLE® PRO platform, and expand its reach to a broader patient population. Future growth will likely involve further integration of its technology into healthcare systems and partnerships aimed at improving widespread access to sleep apnea diagnosis and management, reinforcing its mission to advance sleep health globally.
See full Resonea company page
